Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended)



An indole compound represented by the formula (I), or a pharmaceutically acceptable salt, solvate, or prodrug ~~derivative~~ thereof;



(I)

wherein;

R_1 is selected from groups (a), (b), and (c) wherein;

(a) is C_7-C_{20} alkyl, C_7-C_{20} haloalkyl, C_7-C_{20} alkenyl, C_7-C_{20} alkynyl, carbocyclic radical, or heterocyclic radical, or

(b) is a member of (a) substituted with one or more independently selected non-interfering substituents; or

(c) is the group -(L_1)-R_{11}; where, -(L_1)- is a divalent linking group of 1 to 8 atoms and where R_{11} is a group selected from C_7-C_{20} alkyl, C_7-C_{20} haloalkyl, C_1-C_4alkylaryl, or aryl;

R_2 is hydrogen, or a C1-C45 alkyl;

R_3 is -(L_3)- Z, where -(L_3)- is a ~~a bond~~bond, ~~or~~



and Z is selected from a group represented by the formulae,



wherein, X is oxygen;

R_4 is the group, -(L_h)-(hydroxyfunctional amide); wherein -(L_h)-, is an hydroxyfunctional amide linker having an hydroxyfunctional amide linker length of 1 to 8;

R_5 is the group, -(L_a)-(acidic group); wherein -(L_a)-, is an acid linker having an acid linker length of 1 to 8;

R_6 and R_7 are each independently selected from hydrogen, C_1-C_6 alkyl, C_2-C_6alkenyl, and C_2-C_6 alkynyl.

2. (Previously Amended) The compound of claim 1 wherein R_2 is hydrogen, or C_1-C_4 alkyl.

3. (Previously Amended) The compound of Claim 1 wherein the hydroxyfunctional amide linker group, -(L_h)-, for R_4 is selected from a group represented by the formula;



where Q_2 is -O-, and each R_{40} is independently selected from hydrogen, and C_1-C_8 alkyl.

4. (Original) The compound of Claim 1 wherein the hydroxyfunctional amide linker group, -(Lh)-, for R_4 is a divalent group selected from,



5. (Previously Amended) The compound of Claim 1 wherein the acid linker, -(L_a)-, for R_5 is the group represented by the formula;



wherein R_{54}, and R_{55}, are each independently hydrogen, or C_1-C_8 alkyl.

6. (Previously Amended) The compound of claim 1 wherein R_5 is the group, -(L_a)-(acidic group) and wherein the (acidic group) is the group:



7. (Canceled)

8. (Canceled)

9. (Original) The compound of claim 1 wherein for R_3, Z is the group represented by the formula;



and the linking group -(L_3)- is a bond.

10. (Canceled)

11. (Canceled)

12. (Canceled)

13. (Canceled)

14. (Previously Amended) The compound of claim 1 wherein the linking group -(L_{11})- of R_{11} is a bond and R_{11} is -(CH_2)m-R^{12} wherein m is an integer from 1 to 6, and R^{12} is a group represented by the formula:



wherein a, and p are independently an integer from 0 to 2.

15. (Canceled)

16. (Canceled)

17. (Canceled)

18. (Previously Amended) The compound of claim 1 wherein R_4 is the group, -(L_c)-(hydroxyfunctional amide group) and wherein the (hydroxyfunctional amide group) is:



and R^{4a} is the ~~group OH~~group OH; and

wherein R^{4b} is independently selected from the group consisting of H, and (C_1-C_6)alkyl.

19. (Canceled)

20. (Canceled)

21. (Canceled)

22. (Original) A pharmaceutical formulation comprising a indole compound as claimed in claim 1 together with a pharmaceutically acceptable carrier or diluent therefor.

23. (Previously Amended) A method of inhibiting $sPLA_2$ mediated release of fatty acid comprising contacting $sPLA_2$ with a therapeutically effective amount of indole compound as claimed in claim 1.

24. (Currently Amended) A method of treating ~~a mammal~~rheumatoid arthritis in a mammal~~; to alleviate the pathological effects of Inflammatory Diseases;~~ wherein the method comprises administering to said mammal a therapeutically effective amount of an indole compound as claimed in Claim 1.

25. (Canceled)

26. (Canceled)

27. (Canceled)